Fig. 3

LRRK2 inhibition increases α-synuclein mobility and percentage of α-synuclein-GFP undergoing anterograde axonal transport A Primary hippocampal neurons were transfected with human α-synuclein-GFP on DIV10, treated with 30 nM MLi-2 or equivalent dilution of DMSO 30 min before live cell imaging. Shown are representative snapshots of the axons expressing α-synuclein-GFP and their respective kymographs showing transport over time. Images were captured every 300 ms for 2 min. Scale bar = 10 µm. B Quantification of mobile tracks (traveled ≥ 10 µm) (Nest t test, t(6) = 6.5, *P < 0.05, α-synuclein-GFP puncta count per 50 µm axon length (t(6) = 0.6), and percentages of anterograde (t(51) = 2.2; *P < 0.05) and retrograde tracks of mobile puncta(t(6) = 0.5) (N = 4, number of analyzed kymographs: 27 (DMSO control), 26 (30 nM MLi-2)). C Distribution of binned velocities of anterograde traveling α-synuclein-GFP in neurons treated with DMSO or MLi-2. D Quantification of mean velocities for anterograde (t (6) = 0.4) and retrograde α-synuclein-GFP (t (87) = 1.8). (N = 4, number of analyzed kymographs: 27 (DMSO control), 26 (30 nM MLi-2))